PMCB NASDAQ
PharmaCyte Biotech, Inc.
1W: -9.3%
1M: -16.8%
3M: -45.2%
YTD: -45.8%
1Y: -59.2%
3Y: -80.9%
5Y: -87.9%
$0.40
-0.00 (-0.94%)
Weekly Expected Move ±11.5%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2022-08-16
Earliest Filing
2025-09-05
Latest Filing
investor: 3
partner: 1
acquirer: 1
Counterparties (Filed by PMCB)
5 relationshipsCompanies named in PMCB's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| TNF Pharmaceuticals, Inc. | — | investor | PharmaCyte Biotech, Inc. purchased Series H convertible preferred stock and warrants from TNF Pharmaceuticals, Inc. in a | 2025-09-05 | View |
| GP Nurmenkari Inc. | — | partner | Placement agent for the private placement | 2025-08-18 | View |
| MyMD Pharmaceuticals, Inc. | MYMD | acquirer | PharmaCyte Biotech, Inc. purchased Series G Convertible Preferred Stock, warrants, and registration rights from MyMD Pha | 2024-05-23 | View |
| Femasys Inc. | FEMY | investor | PharmaCyte Biotech, Inc. purchased senior unsecured convertible notes, Series A and Series B warrants from Femasys Inc. | 2023-11-16 | View |
| Iroquois Master Fund Ltd. | — | investor | Entered into a Cooperation Agreement with PharmaCyte Biotech, Inc. involving board appointments and standstill provision | 2022-08-16 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-04-02 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2025-12-05 | Notice of Delisting or Transfer | View | |
| 2025-11-18 | Financial Statements and Exhibits | View | |
| 2025-10-31 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-09-05 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Regula | Agreement Acquisition | View |
| 2025-08-18 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-04-24 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-02-26 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View | |
| 2024-05-23 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Other | Agreement Acquisition | View |
| 2023-11-24 | Departure/Election of Directors; Appointment of Officers | View | |
| 2023-11-16 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2023-11-09 | Changes in Registrant's Certifying Accountant | View | |
| 2023-08-04 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View | |
| 2023-07-19 | Amendments to Articles of Incorporation or Bylaws; Other Events; Financial Statements and Exhibits | View | |
| 2023-05-11 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Amendments to Art | Agreement | View |
| 2023-02-02 | Other Events; Financial Statements and Exhibits | View | |
| 2022-12-30 | Submission of Matters to a Vote of Security Holders | View | |
| 2022-11-07 | Departure/Election of Directors; Appointment of Officers | View | |
| 2022-10-14 | Departure/Election of Directors; Appointment of Officers; Shareholder Nominations; Other Events; Fin | View | |
| 2022-10-07 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR